News & Updates
Aiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patch
Excerpt from the Press Release: An East Bay company formulated a Covid-19 vaccine candidate to load onto a patch of 2,000 microneedles, one of several efforts globally to make it easier to take drugs and vaccines to combat the pandemic. Zosano Pharma Corp. (NASDAQ: ZSAN) of Fremont did not disclose the name of the vaccine,…
Read More
Excerpt from the Press Release: SAN DIEGO, Nov. 18, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from two scientific posters for its Phase 2 clinical studies of VAL-083, the Company’s lead compound for the treatment of glioblastoma multiforme (GBM). …
Read More
Study will investigate how a broad range of exposures affect brain and child development BOSTON, Nov. 17, 2021 /PRNewswire/ — Boston Children’s Hospital has been awarded two five-year grants by the National Institutes of Health (NIH) to co-lead the HEALthy Brain and Child Development (HBCD) study, an ambitious, comprehensive national study of brain development from birth through early…
Read More
Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disorders Excerpt from the Press Release: MADRID, Spain and CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code:…
Read More
Excerpt from the Press Release: Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2. Now, new research led by investigators at Harvard Medical School and Boston Children’s Hospital points to a well-known…
Read More
Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two-dose series…
Read More
Seventeen objective responses reported across nine cancers Evidence of monotherapy activity, with four cases of confirmed objective response Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovarian cancer, MSS endometrial cancer, and melanoma; as well as responses in tumors not previously reported including pancreatic cancer, cervical cancer, visceral…
Read More
Excerpt from the Press Release: We are pleased that The Lancet, a trusted source of clinical, public health and global health knowledge, published Phase 3 data showing the COVID-19 vaccine candidate, COVAXIN™ (BBV152), has 93.4% efficacy against severe COVID-19 disease. COVAXIN™ (BBV152), a whole virion inactivated COVID-19 vaccine candidate, uses the same technology that is safely and effectively applied in the production of Bharat…
Read More
New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at its virtual Spotlight Event being held today that, following recent discussions with the…
Read More
— Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function — — Lead product candidate WU-NK-101 demonstrated potent anti-tumor activity and long-term persistence in vivo — — Data support ongoing clinical development of WU-NK-101 as best-in-class memory NK…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?